The claim that BPC-157 came from human gastric juice hasn't held up

What happened

In an August 2026 Stanford Medicine feature on the peptide boom, Katrin Svensson, PhD, an associate professor of pathology at Stanford who runs her own peptide research lab, said something that should matter to anyone who has used BPC-157 because it seemed like the natural option. Svensson told Stanford's science writer that she and other scientists have not been able to replicate the original finding that BPC-157 came from human gastric juice, and that failure has led her to suspect the compound might not occur naturally in the body at all.

That matters because the gastric-juice origin story isn't a footnote, it's the single most repeated reason BPC-157 gets treated as gentler and safer than a fully synthetic compound. The claim traces back to a 1994 US patent filed by Croatian researcher Predrag Sikiric and his team, describing a larger protein isolated from both animal and human gastric juice. The 15-amino-acid fragment now sold as BPC-157 was derived from that larger protein in later work by the same group. Patricia Brubaker, PhD, a professor emerita of physiology and medicine at the University of Toronto who reviewed the patent, found it gives almost no detail about the isolation process, and there's no way to tell from it whether what was isolated was ever a pure, verified compound.

What most coverage of BPC-157 has been getting wrong

Every foundational science claim is supposed to get checked by other labs before it becomes accepted fact. That check, replication, is what turns "one group reported this" into "this is real." For BPC-157's origin story, that check appears never to have happened successfully. The original work came from a single Croatian research group publishing in journals that Brubaker, writing for McGill University's Office for Science and Society, described as hard to access for outside review. Svensson's comment is the first time a scientist actively working in the field has said, on the record, that she tried to replicate it and couldn't.

None of this proves BPC-157 doesn't exist naturally in the body. It proves the specific claim people cite to justify that assumption hasn't been independently confirmed, which is a different and more honest thing to say.

Why this makes the safety picture, not the effectiveness picture, the real story

Svensson's larger point wasn't really about whether BPC-157 works. It was about what "naturally occurring" is supposed to buy you, and whether BPC-157 has earned that label. If a peptide is genuinely produced by the body already, that's one reason people assume the immune system won't treat it as a foreign invader. Svensson's read is that once the origin claim stops holding up, that assumption stops being safe, and a compound sold as research-grade with no confirmed natural origin and no completed human safety trials is a different risk category than its marketing suggests.

Jonathan Long, PhD, a Stanford associate professor who co-authored the same feature, put the practical version plainly: with research-grade peptides bought online, "there could be all sorts of contaminants in that solution that you're injecting into yourself," and there's no toxicity data because the trials that would generate it haven't been run.

Where the human evidence actually stands

Three decades in, the human data on BPC-157 is thin. According to Brubaker's review, only three published reports describe giving it to people, all from the same research group, all small (as few as two participants, as many as sixteen), and none with a placebo group to separate a real effect from expectation. Everything else, tendon growth, gut healing, the long list of conditions in the original patent, comes from animal and cell studies.

That's finally starting to change. In February 2026, a company called Hudson Biotech began enrolling participants in the first properly designed, placebo-controlled human trial of BPC-157, testing whether it speeds recovery from a Grade II hamstring strain in 120 people. The trial is expected to complete in early 2027. It will answer one specific question, about one specific injury, in one specific dose. It won't settle whether BPC-157 does any of the other things it's used for, and it does nothing to resolve the gastric-juice question, since that's about the compound's origin, not its effects.

What this means for you right now

If you buy BPC-157 as a research-use compound, nothing about the product itself changed this week. What changed is how much weight the "it's natural, your body already makes this" argument should carry in your decision, and the answer is less than it used to. That argument rested on a 1990s finding a working peptide researcher now says she can't reproduce. You can still decide the animal data and community reporting are compelling enough to proceed, plenty of people reasonably will, but do it knowing the safety case rests on "nobody has proven this is dangerous," not "this is definitely produced in your own body already."

If you're going through a compounding pharmacy or telehealth route instead of buying research-grade product directly, this doesn't change your regulatory situation, the FDA hasn't taken new action on BPC-157. But if a provider leans on the natural-origin claim as a safety reassurance, that's worth a follow-up question.

Either way, compare real per-mg pricing and demand third-party purity and identity testing before you buy, at the price comparison tool and the vendor directory.

What to watch next

The Hudson Biotech hamstring trial won't touch the origin question, but it's the thing that would move the effectiveness question forward. Results aren't expected before 2027. We'll cover it when they land, along with anything further from Svensson's lab or other independent groups on where BPC-157 actually comes from.